October 15, 2025
By Ashley Tucker, OD, FAAO, FSLS, ABO Diplomate
The long-anticipated FDA approval of Essilor’s Stellest spectacle lens marks a historic milestone in myopia management. For the first time, eye care professionals in the United States can prescribe a spectacle-based intervention that is clinically proven—and now FDA approved—to slow myopia progression in children. It’s a moment of validation for the field, but also a call to action. What we do next will determine whether this breakthrough truly transforms care or simply becomes another underutilized option.
How the Lenses Work
The Stellest lens earned De Novo authorization based on two-year clinical trial data showing a 71% reduction in myopia progression and 53% reduction in axial elongation compared with single-vision lenses. Its unique “Highly Aspherical Lenslet Target” (HALT) design uses a central clear zone surrounded by concentric rings of tiny aspherical lenslets to create myopic defocus, signaling the eye to slow axial growth. This data, along with the safety profile inherent to spectacles, proves the FDA’s decision is both scientifically sound and clinically meaningful.
Turning Evidence into Practice
However, authorization is only the beginning. Now, the profession must translate evidence into real-world practice. First, we need clear patient selection criteria. The lens is approved for children who begin treatment between the ages 6 and 12, but within that window lies wide variation. Younger, faster progressors and children not yet ready for contact lenses will likely benefit most. Incorporating baseline refraction, axial length, family history and compliance potential into our clinical decision-making will be essential.
Second, we must manage expectations. Stellest, just like all other myopia control modalities, does not stop myopia progression – it slows myopia progression. It is imperative that families understand continued progression, though reduced, is expected. Daily wear time is crucial; the published data show that consistent use drives efficacy. As with any optical defocus modality, some adaptation issues (blur or halos) may occur and should be discussed transparently.
Third, robust monitoring must follow implementation. Regular follow-ups with refraction and axial length measurements every six to 12 months will help identify non-responders early. For those with continued rapid elongation, combination therapy with low-dose atropine, or transition to contact lens–based options, may be appropriate.
Finally, this moment calls for advocacy and collaboration. Access and affordability will shape the real-world impact of Stellest far more than its optical design. We must work collectively as clinicians, educators and industry partners to ensure equitable availability, insurance recognition and public awareness.
Progress for the Future
The FDA’s authorization of Stellest represents more than a new product; it represents progress toward a future where myopia control is as routine as vision correction. Spectacle lenses may now serve as the gateway to early intervention – an accessible starting point for millions of children who might otherwise be left untreated.
The science brought Stellest to market; our implementation will define its success. Let’s meet this moment with the same rigor, transparency and compassion that have always defined the best of optometric care.
